CF
BEAM icon

Corebridge Financial’s Beam Therapeutics BEAM Stock Holding History

Corebridge Financial’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,808
Closed -$875K – 333
2025
Q1 		$875K Buy
44,808
+6,795
+18% +$178K 0.01% 1319
2024
Q4 		$943K Sell
38,013
-2,870
-7% -$73.2K 0.01% 1350
2024
Q3 		$1M Sell
40,883
-251
-0.6% -$6.49K 0.01% 1360
2024
Q2 		$964K Buy
+41,134
New +$1.01M 0.01% 1353

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Corebridge Financial's BEAM Position: Q2 2025 in Review

Corebridge Financial sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 44,808 shares — an estimated $875K sold.

Corebridge Financial first reported a position in BEAM in Q2 2024 and held it in 4 quarters. The position peaked at $1M in Q3 2024. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • Corebridge Financial reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 44,808 Beam Therapeutics shares in Q2 2025, an estimated $875K.
  • Corebridge Financial first reported a position in Beam Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Beam Therapeutics position peaked at $1M in Q3 2024.
  • 217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.